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Organ iron accumulation in chronically transfused children with 
sickle cell anaemia: Baseline results from the TWiTCH trial
John C. Wood, Alan R. Cohen, Sara L. Pressel, Banu Aygun, Hamayun Imran, Lori 
Luchtman-Jones, Alexis A. Thompson, Beng Fuh, William H. Schultz, Barry R. Davis, and 
Russell E. Ware for the TWiTCH Investigators
Summary
TCD (transcranial doppler) With Transfusions Changing to Hydroxyurea (TWiTCH) trial is a 
randomized, open-label comparison of hydroxycarbamide (also termed hydroxyurea) versus 
continued chronic transfusion therapy for primary stroke prevention in patients with sickle cell 
anaemia (SCA) and abnormal TCD. Severity and location of iron overload is an important 
secondary outcome measure. We report the baseline findings of abdominal organ iron burden in 
121 participants. At enrolment, patients were young (9.8 ± 2.9 years), predominantly female 
(60:40), and previously treated with transfusions (4.1 ± 2.4 years) and iron chelation (3.1 ± 2.1 
years). Liver iron concentration (LIC; 9.0 ± 6.6 mg/g dry weight) and serum ferritin were 
moderately elevated (2696 ± 1678 μg/l), but transferrin was incompletely saturated (47.2 ± 
23.6%). Spleen R2* was 509 ± 399 Hz (splenic iron ∼13.9 mg/g) and correlated with LIC (r2 = 
0.14, p=0.0008). Pancreas R2* was increased in 38.3% of patients but not to levels associated with 
endocrine toxicity. Kidney R2* was increased in 80.7% of patients; renal iron correlated with 
markers of intravascular haemolysis and was elevated in patients with increased urine albumin-
creatinine ratios. Extra-hepatic iron deposition is common among children with SCA who receive 
chronic transfusions, and could potentiate oxidative stress caused by reperfusion injury and 
decellularized haemoglobin.
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Introduction
Stroke remains one of the most devastating complications to occur in children with sickle 
cell anaemia (SCA), with serious motor, neurocognitive and psychological sequelae. With 
the advent of regular Transcranial Doppler (TCD) screening, many children at risk for stroke 
are identified early and begin chronic transfusion therapy, which has markedly improved 
stroke-free survival in this vulnerable patient population (Armstrong-Wells et al, 
2009;Bernaudin et al, 2011;Enninful-Eghan et al, 2010). However, chronic transfusion 
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therapy for primary stroke prevention must be continued indefinitely, and is associated with 
a variety of problems for both patients and providers, such as expense, disruption of school 
and work schedules, ongoing venous access, risk of infection, erythrocyte alloimmunization 
and transfusion-acquired iron overload that requires tedious and expensive iron chelation 
therapy(Abboud et al, 2011;Adams and Brambilla 2005).
An alternative to chronic transfusion therapy for children at risk for primary stroke would 
represent an improvement in their long-term management. The TCD With Transfusions 
Changing to Hydroxyurea (TWiTCH) trial is a 2-year, randomized, open-label comparison 
of hydroxycarbamide (also termed hydroxyurea) versus continued chronic transfusion 
therapy in patients with abnormal TCD (ClinicalTrials.gov NCT 01425307). The primary 
outcome of the multicentre TWiTCH trial is non-inferiority of hydroxycarbamide to 
transfusion therapy with respect to TCD velocities. Secondary outcomes include 
neurological events, sickle cell-related events, changes in liver iron concentration (LIC), and 
quality of life. Study subjects randomized to the Standard Treatment Arm receive monthly 
erythrocyte transfusions along with chelation therapy for transfusional iron overload, while 
those randomized to the Alternative Treatment Arm receive hydroxycarbamide along with 
serial phlebotomy therapy to lower iron stores. In addition to LIC, all patients in the 
TWiTCH trial undergo abdominal MRI for R2* iron quantification in other organs, such as 
the spleen, pancreas and kidney. To date, there are few data regarding the extent and 
patterns of extra-hepatic deposition of iron in patients with SCA on chronic transfusion 
therapy. This manuscript reports the baseline amounts of iron within the liver and other 
abdominal organs, and provides predictors and physiological correlates of extra-hepatic iron 
deposition in this patient population.
Methods
The TWiTCH study was approved by Cincinnati Children's Hospital Medical Centre as the 
Institutional Review Board (IRB) of record, as well as all local IRBs and the Data Safety 
Monitoring Board. All patients and parents provided informed consent, with assent as 
required locally by age. A total of 24 centres in the US and one in Canada enrolled patients 
into TWiTCH; 21 of these sites were able to collect abdominal R2* data. A total of 159 
patients enrolled in the screening phase of the study; 124 TWiTCH enrolees had screening 
R2* studies, and 121 of those had valid LIC R2* values (120 pancreas R2*, 119 renal R2*, 
and 81 spleen R2*), which form the basis for this report.
Abdominal R2* measurements were collected using multiple gradient echo pulse sequences 
on 1.5 Tesla Magnets (General Electric, 32 examinations; Philips, 15 examinations; 
Siemens, 74 examinations) using phase array torso or body coils. Imaging parameters varied 
across machines with the guidelines for liver and spleen R2* parameters described in Table 
I; pancreas and kidney R2* acquisitions were identical except for target slice thickness of 
5-6 mm. Liver and spleen R2* were calculated from three contiguous axial slices(Brewer et 
al, 2009). Kidney R2* was measured in both the left and right kidney from two contiguous 
coronal slices(Schein et al, 2008). Pancreas R2* was estimated from 3 contiguous axial 
slices(Noetzli et al, 2011). All R2* images were analysed centrally at Children's Hospital 
Los Angeles by a single experienced observer. Each organ was partitioned into sub-regions 
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of similar iron burden; signal decay from each sub-region was fitted to an exponential plus a 
constant offset as previously described(Meloni et al, 2013).
Predictors and functional correlates of abdominal organ R2* measurements were assessed 
using univariate and multivariate regression. Log transformation of the R2* measurements 
was used to improve normality. Predictors included age, sex, years of transfusion therapy, 
years of chelation, chelator type in the previous year, presence/absence of a spleen and LIC, 
as well as baseline laboratory parameters including serum ferritin, haemoglobin 
concentration, C reactive protein (CRP), lactate dehydrogenase (LDH), reticulocyte count 
and total bilirubin. Functional correlates included systolic and diastolic blood pressure, 
creatinine, estimated glomerular filtration rate (eGFR) using the Schwartz formula(Schwartz 
et al, 1976), screening TCD velocity, brain magnetic resonance angiography (MRA) 
vasculopathy scores(Helton et al, 2014), spleen volume and texture by ultrasound, 
%Haemoglobin S, platelet count, white blood cell count, serum iron, total iron binding 
capacity, alanine aminotransferase and transferrin saturation. Variables with near-significant 
(p<0.10) univariate correlations with organ iron results were further evaluated in 
multivariate regression models. All statistics were performed by the TWiTCH Data 
Coordinating Centre (University of Texas Health Science Center, Houston, TX, USA).
Results
Figure 1 illustrates typical imaging quality and representative regions of interest obtained in 
this study. Liver iron was quantifiable in 121 of 124 examinations; reasons for rejection 
included lack of necessary MRI acquisition software, noncompliance with imaging 
parameters, or Digital Imaging and Communications in Medicine (DICOM) incompatibility. 
Spleens were anatomically absent in 35 patients. Pancreas R2* quantitation was challenging 
in younger patients who were unable to breath-hold, and was rejected in several patients 
because of proximity to gastric air (Figure 2), which spuriously increased R2* values in the 
40-80 Hz range.
Baseline demographics of the study population are summarized in Table II, and illustrates 
that the TWiTCH subjects were young with a 60/40 female predominance. Chronic 
transfusion exposure averaged 4.1 years, with evidence of transfusional iron overload, 
including an average serum ferritin of 2696 μg/l and average LIC of 9.0 mg/g dry weight of 
liver, which is consistent with several years of transfusions with parenchymal iron 
deposition. More than 95% of the subjects were already receiving iron chelation, almost 
exclusively with the oral iron chelator deferasirox.
Table III compares the organ iron burden within the liver to other abdominal organs, and 
provides evidence of substantial and widespread iron accumulation for most children 
enrolled in TWiTCH. Spleen iron deposition was present in 100% of participants with 
splenic tissue. The average splenic R2* value corresponds to an equivalent iron 
concentration of 13.9 mg/g dry weight, which was actually higher than the corresponding 
LIC value for each child(Brewer et al, 2009). There was a significant correlation between 
hepatic and splenic iron measurements (r=0.37, p=0.0009, Figure 3). Liver iron trended 
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lower in patients with MRI detectable spleens (8.1 ± 5.3 versus 11.2 ± 8.8 mg/g dry weight, 
p=0.11), suggesting that loss of the splenic iron depot may increase hepatic iron loading.
Table IV provides the univariate correlations of selected predictors with abdominal organ 
iron measures. Predictors with p values < 0.10 were further investigated in multivariate 
models (Table V). For the spleen R2* measurement, LIC was the strongest predictor (Figure 
1). Age, blood pressure, years of transfusion therapy, pre-enrolment haemoglobin, 
haemoglobin at enrolment, absolute reticulocyte count (ARC), serum ferritin, CRP, MRA 
vasculopathy score, and platelet count had p values < 0.10 on univariate analysis, but none 
was significant (p < 0.05) in multivariate analyses (Table V). Spleen R2* trended upward 
with serum ferritin (p=0.08) and with years of transfusion therapy (p =0.06). The 
multivariate model demonstrated an adjusted r2 of 0.26. Spleen R2* did not correlate with 
spleen volume or texture by ultrasound, and was independent of peripheral blood counts 
including platelets, white blood cell count, haemoglobin, and percentage of HbS.
Minimal pancreatic iron overload was detected, with only 38.3% of the children having R2* 
values above the normal range (Table III). Pancreas R2* was independent of subject age, 
sex, years of transfusion and years of chelation. Pancreas R2* correlated with LIC (r = 0.32, 
p=0.005), but the relationship had threshold behaviour because 11/14 (79%) participants 
with LIC ≥ 18 mg/g had clear pancreatic iron overload (≥28.1), compared to 35/106 (33%) 
with LIC < 18 mg/g (p=0.002 by Fischer's exact test). No child had a pancreas R2* 
exceeding 100 Hz, which is the level associated with cardiac iron and endocrine toxicities in 
thalassemia major patients(Meloni et al, 2014;Noetzli et al, 2009).
Kidney iron (R2*) was detectable in 119 (98%) of baseline R2* measurements (Table III). 
Similar to the pancreas, kidney R2* was independent of age, sex, LIC, serum ferritin, years 
of transfusion and years of chelation. Kidney R2* was proportional to LDH (p<0.001) and 
inversely proportional to baseline haemoglobin concentration (p<0.02) and total iron binding 
capacity (p=0.006) in the multivariate model. These “predictors” of kidney R2* are 
consistent with the hypothesis that filtered decellularized haemoglobin is responsible for the 
cortical iron deposition observed in patients with SCA(Schein et al, 2008). Kidney R2* was 
also proportional to serum creatinine and eGFR (p=0.0001 and 0.04, respectively, in the 
univariate analysis). Kidney R2* trended upward with urine albumin/creatinine ratio 
(p=0.098), and patients with albumin/creatinine ratios greater than 30 had significantly 
higher kidney R2* (Figure 4). Kidney R2* also trended higher with the brain MRA 
vasculopathy grade (p=0.19). In univariate analyses, it was also related to use of chelation 
therapy, haemoglobin at enrolment (p=0.02 in multivariate analyses), average pre-treatment 
haemoglobin, ARC, total iron binding capacity (p=0.006 multivariate), LDH (p<0.001 
multivariate), bilirubin, MRA vasculopathy score, and presence of a spleen. In multivariate 
analyses, haemoglobin at enrolment, total iron binding capacity and LDH were significant 
(p=0.02, p=0.006, and p<0.001, respectively).
Discussion
This study documents the severity and heterogeneity of abdominal parenchymal iron loading 
in a large, paediatric cohort of children with SCA receiving chronic transfusions. In addition 
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to the large size of this cohort, a real strength of this study relates to the fact that 
observations were made with standardized MRI protocols (Table I) across many different 
medical centres. With an average age of less than 10 years, and just over 4 years of monthly 
transfusions, children enrolled in TWiTCH had elevated iron accumulation in both the liver 
and spleen, most had iron deposition in the kidney, and some even had pancreatic 
deposition. If the severity of parenchymal iron deposition was surprising, the heterogeneity 
is perhaps not, because liver, pancreas, kidney and spleen have different mechanisms and 
rates of iron uptake. Initially, transfusion-acquired iron is stored within the 
reticuloendothelial system (Kupffer cells, bone marrow and splenic macrophages) but 
redistributes over time into hepatocytes, endocrine glands and the heart(Noetzli et al, 
2008;Noetzli et al, 2011;Noetzli et al, 2009). As a result, the spleen could be expected to be 
the most heavily loaded organ, followed by the liver, which was observed in this young 
cohort (Table III). These observations document the fact that the spleen in SCA, however 
small and even non-functional from an immune standpoint, still serves as an important depot 
for transfusional iron. Using an approximate calibration curve, splenic iron averaged 13.9 
mg/g in this population, nearly 40% higher than the average LIC for the whole 
population(Brewer et al, 2009).
The lack of correlation between parenchymal iron deposition in the liver and spleen with the 
duration of transfusion therapy reflects the use of iron chelation therapy in more than 95% of 
patients. Liver iron was associated with deferasirox and deferoxamine use in the previous 
year on univariate analysis. Iron stores, therefore, most likely represent compliance with iron 
chelation therapy, which is difficult to quantitate and not captured in this study. The 
significance of splenic iron overload is difficult to ascertain, given the lack of good markers 
of splenic function, and the overlay of microvascular obstruction and splenic infarction. 
However, the fact that even non-functional splenic tissue can accumulate iron suggests an 
important protective role for the spleen in chronically transfused patients with SCA. 
Prospective studies using MRI R2* technology should be used when surgical splenectomy is 
recommended for hypersplenism or other reasons, to determine the importance of the spleen 
acting as a ‘sump’ for transfusional iron overload in this patient population.
Pancreas iron loading was uncommon in the TWiTCH cohort. The risk of pancreatic (and 
cardiac) iron deposition from chronic transfusions is known to vary significantly by disease 
state, being most rapid in Blackfan-Diamond anaemia and least rapid in thalassemia 
intermedia syndromes (Porter 2007;Wood 2008). Multiple factors appear to contribute to 
this phenomenon, including the rate of effective erythropoiesis(Gafter-Gvili et al, 
2004;Meloni et al, 2014;Sahlstedt et al, 2009), degree of systemic inflammation(Walter et 
al, 2006), as well as the rate and duration of transfusional iron loading(Noetzli et al, 
2011;Wood et al, 2004). Effective erythropoiesis as occurs in SCA serves to regenerate 
apotransferrin, which lowers transferrin saturation and the risk of labile plasma iron(Gafter-
Gvili et al, 2004;Sahlstedt et al, 2009). Chronic inflammation in patients with SCA is 
associated with high circulating hepcidin levels, low transferrin saturations, and increased 
iron retention in the reticuloendothelial system(Ganz 2006). Chronically transfused patients 
with SCA are known to have a higher inflammatory cytokine background and lower 
transferrin saturations than thalassemia major patients(Walter et al, 2006). Regardless of the 
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mechanism, the relatively low baseline transferrin saturation in our cohort (47.6%) helps to 
explain the low prevalence of pancreatic iron loading. Significant labile plasma iron, which 
more easily enters the parenchymal cells, does not appear in the blood until serum 
transferrin is more than 85% saturated(Piga et al, 2009;Pootrakul et al, 2004). Endocrine 
glands and the heart only develop pathological iron overload through passage of labile iron 
species through nonspecific divalent channels, possibly L or T type calcium 
channels(Kumfu et al, 2012;Oudit et al, 2003). Previous single centre studies suggest that 
patients with SCA have relatively low cardiac and pancreatic iron burden (Meloni et al, 
2014;Noetzli et al, 2011;Wood 2008;Wood et al, 2004) as well as minimal pancreatic and 
cardiac toxicities(Vichinsky et al, 2005). Although cardiac iron was not assessed in this 
study, cardiac iron has never been documented in the absence of significant (R2* > 100 Hz) 
pancreatic iron overload(Meloni et al, 2014;Noetzli et al, 2011;Noetzli et al, 2009). 
Measurements such as fasting glucose and glucose tolerance testing were not performed in 
TWiTCH, so it was not possible to investigate the functional significance of the observed 
pancreas iron deposition.
In contrast to iron deposition within the liver, spleen and pancreas, iron loading within the 
kidney depends almost entirely on cell free haemoglobin and haeme species, rather than on 
transfusional iron-laden macrophages or labile plasma iron. Filtered haemoglobin binds to 
megalin and cubulin receptors and is taken up by endocytosis into the proximal and distal 
convoluted tubules of the kidney(Gburek et al, 2002), creating the classic cortical loading 
pattern observed by MRI(Schein et al, 2008;Solecki et al, 1983). In our cohort, kidney R2* 
correlated most strongly with LDH (positive association) and baseline haemoglobin level 
(negative). Our novel association between kidney R2* and albuminuria suggests a 
relationship between early sickle nephropathy and renal iron deposition. Given that all of 
these children were receiving transfusions that suppress some of their endogenous sickle 
erythropoiesis, these predictors may also result from intrinsic differences in the patients' 
own red blood cell membranes or vascular endothelium, as well as iatrogenic sources of 
haemolysis, such as erythrocyte alloimmunization and antigen-mismatched transfusions.
Our study had a few limitations. Although the MRI core laboratory standardized acquisitions 
as much as possible, complete MRI parameter standardization was impossible. 
Quantification of the transfusional iron burden, prior to the baseline examination, was not 
obtained. Patient compliance with iron chelation therapy was also not documented. Since 
there was little prior data on predictors of extrahepatic iron deposition in sickle cell disease 
patients, our statistics were performed as associations of discovery, leaving them vulnerable 
to Type 1 error. Predictors identified in this manuscript should be validated in an 
independent data set.
In summary, we have defined a substantial iron burden within the abdominal organs of a 
large cohort of children with SCA who are receiving chronic transfusions for proven 
cerebrovascular disease. In addition to liver deposition, every child with splenic tissue 
present on MRI had evidence of splenic parenchymal iron deposition, and most had 
evidence of renal iron accumulation as well. Serial measurements with R2* will occur at the 
end of the study, which will allow a direct comparison of protocol-directed therapeutic 
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interventions (chelation versus phlebotomy) and provide further insights into the loading and 
unloading of iron within this patient population.
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Figure 1. 
(Left) Representative transverse slice from the T2* acquisition with the liver, spleen and 
pancreas outlined. Iron has caused the liver and spleen to appear quite dark relative to the 
other abdominal tissues. (Right) Representative coronal slice demonstrating typical pattern 
of cortical darkening caused by filtered haemoglobin depositing in the proximal and distal 
tubules of the kidney.
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Figure 2. 
Illustration of close proximity of gastric air to pancreas in some patients; this caused 
artifactual increases in pancreas R2* in four patients.
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Figure 3. 
Scattergram depicting splenic R2* versus liver iron concentration. Both axes have a 
logarithmic scale.
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Figure 4. 
Bar graph depicting the kidney R2* value in patients with and without proteinuria, defined 
as a urinary albumin-creatinine ratio (ACR) greater than 30. Error bars represent standard 
error of the mean.
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Table I
Imaging Parameters for all 121 baseline abdominal MRI R2* examinations SNR, signal-
to-noise ratio
Parameter Target Actual (mean ± SD)
Field of View (mm) 280-420 354.4 ± 35.6
Phase Field of View (%) 60-100% 78.7 ± 12.0
Slice Thickness (mm) 8-12 9.6 ± 1.2
In-plane Resolution (mm) 2-6 3.0 ± 0.7 × 3.3 ± 0.8
Number of echoes > 12 13.5 ± 2.6
Shortest echo time (ms) < 1.2 1.10 ± 0.19
Echo spacing (ms) < 1.5 1.05 ± 0.31
Bandwidth (Hz/px) > 600 1741 ± 761
Repetition time (ms) 97.5 ± 25.9
Points in frequency direction 118.0 ± 15.8
Frequency direction sampling 120.8 ± 21.7
Relative SNR metric 1 2.4 ± 1.7
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Table II
Patient Characteristics for the baseline abdominal R2* magnetic resonance imaging 
cohort
Parameter Mean ± SD
N 121
Age at enrollment (years) 9.8 ± 2.9
Sex (% male) 40.0
Body mass index (kg/m2) 17.8 ± 3.8
Time on transfusion (years) 4.1 ± 2.4
On chelation therapy (%) 95.3%
Years on chelation (years) 3.1 ± 2.1
Haemoglobin (g/l)* 78 ± 8.0
HbS % 28.5 ± 9.9
Absolute reticulocyte count (×109/l) 354 ± 123
Serum ferritin (μg/l) 2696 ± 1678
Serum iron (μmol/l) 26.2± 10.8
Total iron binding capacity (μmol/l) 66.1 ± 40.6
Transferrin saturation (%) 47.2 ± 23.6
Lactate dehydrogenase (u/l) 599 ± 213
C-reactive protein (mg/l) 4.8 ± 8.4
Alanine transaminase (u/l) 48.0 ± 42.2
Creatinine (μmol/l) 35.4 ± 13.3
Bilirubin (μmol/l) 47.9 ± 30.8
*
Pre-transfusion haemoglobin in the past 6 months
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Table IV
Univariate correlations (r2 and p value) between iron indices (ln scale), clinical history 
and laboratory values
Organ LIC R2* Pancreas R2* Kidney R2* Spleen R2*
LICR2* (mg/g) --- 0.14 (<0.0001) 0.002 (0.63) 0.14 (0.0008)
Pancreas R2* (Hz) 0.14 (<0.0001) --- 0.01 (0.19) 0.08 (0.01)
Kidney R2* (Hz) 0.002 (0.63) 0.01 (0.19) --- 0.007 (0.47)
Spleen R2* (Hz) 0.14 (0.0008) 0.08 (0.01) 0.007 (0.47) ---
Age (years) 0.03 (0.0503) 0.003 (0.54) 0.0007 (0.78) 0.06 (0.04)
Gender (male/female) 0.009 (0.31) 0.02 (0.24) 0.01 (0.20) 0.03 (0.12)
Body mass index (kg/m2) 0.001 (0.70) 0.003 (0.55) 0.02 (0.13) 0.02 (0.28)
Systolic Blood Pressure (mm Hg) 0.004 (0.51) 0.01 (0.27) 0.02 (0.17) 0.09 (0.009)
Diastolic Blood Pressure (mm Hg) 0.004 (0.52) 0.03 (0.08) 0.003 (0.60) 0.08 (0.01)
Years of Transfusion Therapy 0.01 (0.22) 0.01 (0.33) 0.003 (0.53) 0.04 (0.09)
Years of Chelation 0.02 (0.18) 0.02 (0.16) 0.001 (0.75) 0.005 (0.57)
Currently on chelation (yes/no) 0.0005 (0.81) 0.0002 (0.89) 0.04 (0.04) 0.003 (0.62)
Exjade in the past year (yes/no) 0.04 (0.03) 0.004 (0.52) 0.009 (0.30) 0.0007 (0.81)
Desferal in the past year (yes/no) 0.05 (0.01) 0.02 (0.12) 0.0004 (0.84) 0.02 (0.19)
Haemoglobin at enrollment (g/l) 0.002 (0.65) 0.02 (0.13) 0.10 (0.0004) 0.04 (0.06)
Average pre-treatment Hb over last 6 months (g/l) 0.004 (0.52) 0.003 (0.58) 0.04 (0.03) 0.03 (0.12)
HbS (%) 0.001 (0.79) 0.003 (0.59) 0.01 (0.28) 0.008 (0.43)
Absolute reticulocyte count (×109/l) 0.02 (0.14) 0.005 (0.46) 0.04 (0.04) 0.09 (0.01)
Serum ferritin (μg/l) 0.33 (<0.0001) 0.06 (0.01) 0.002 (0.65) 0.04 (0.09)
Serum Iron (μg/l) 0.001 (0.73) 0.007 (0.40) 0.03 (0.12) 0.007 (0.52)
Total Iron Binding Capacity (μmol/l) 0.12 (0.0003) 0.02 (0.13) 0.12 (0.0004) 0.01 (0.37)
Transferrin saturation (%) 0.19 (<0.0001) 0.002 (0.65) 0.02 (0.22) 0.0001 (0.95)
Lactate dehydrogenase (u/l) 0.06 (0.01) 0.0009 (0.75) 0.24 (<0.0001) 0.001 (0.74)
C-reactive protein (mg/l) 0.008 (0.38) 0.02 (0.21) 0.0001 (0.90) 0.09 (0.01)
Alanine transaminase (u/l) 0.03 (0.0481) 0.004 (0.53) 0.02 (0.17) 0.006 (0.50)
Creatinine (μmol/l) 0.006 (0.41) 0.001 (0.69) 0.12 (0.0001) 0.01 (0.38)
Bilirubin (μmol/l) 0.05 (0.02) 0.008 (0.35) 0.04 (0.02) 0.001 (0.76)
Estimated glomerular filtration rate (ml/min/1.73m2) 0.01 (0.28) 0.002 (0.67) 0.04 (0.04) 0.007 (0.46)
Transcranial doppler maximum velocity, screening (cm/s) 0.006 (0.39) 0.02 (0.21) 0.01 (0.23) 0.004 (0.56)
Magnetic resonance imaging vasculopathy score (1-5) 0.04 (0.53) 0.13 (0.02) 0.13 (0.02) 0.12 (0.09)
Platelet count (×109/l) 0.02 (0.16) 0.02 (.18) 0.0009 (0.76) 0.08 (0.01)
White cell count (×109/l) 0.03 (0.06) 0.04 (0.04) 0.01 (0.27) 0.02 (0.17)
Spleen present (yes/no) 0.02 (0.14) 0.0001 (0.93) 0.05 (0.01) --
Spleen volume (yes/no) 0.009 (0.38) 0.04 (0.09) 0.001 (0.74) <0.0001 (0.96)
Spleen inhomogeneous (yes/no) 0.01 (0.27) 0.02 (0.19) 0.01 (0.30) 0.03 (0.13)
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Organ LIC R2* Pancreas R2* Kidney R2* Spleen R2*
Spleen coarse echotexture (yes/no) 0.04 (0.05) 0.02 (0.20) <0.0001 (0.95) 0.02 (0.26)
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